{"entity":{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","aka":["Alza Corporation","Janssen","Ortho Biotech Products, L.P.","Ortho Biotech","Sequus Pharmaceuticals","Centocor, Inc.","Centocor","Alza Corporation, DE, USA","Cougar Biotechnology, Inc.","Cougar Biotechnology","McNeil Consumer & Specialty Pharmaceuticals","McNeil"],"tldr":"Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).","summary":"Johnson & Johnson, based in New Brunswick, New Jersey, and listed as JNJ, leads in multiple myeloma with Darzalex, Carvykti, Tecvayli and Talvey and in bispecific antibodies for lung cancer with Rybrevant. Its oncology portfolio spans daratumumab, teclistamab, talquetamab, ciltacabtagene autoleucel developed with Legend, amivantamab with lazertinib, abiraterone and apalutamide in prostate cancer, TAR-200 intravesical gemcitabine for bladder cancer approved in 2025, and pasritamig, a KLK2 by CD3 bispecific. Nuclide links it to the CARTITUDE-1 and CARTITUDE-4, MAIA, CEPHEUS and MajesTEC-1 papers, to the LEGEND-2 trial, to robotic bronchoscopy, and to the Yale Open Data Access project. Whether CAR-T and bispecifics move into first-line myeloma and displace daratumumab combinations is the question its own portfolio poses. Teclistamab, cilta-cel and amivantamab have their own pages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Johnson_%26_Johnson","links":[{"label":"Official website","url":"https://www.jnj.com"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":["jnj-87189401"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04557059"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"New Brunswick, NJ","country":"US","companyType":"pharma","website":"https://www.jnj.com","ticker":"JNJ","investors":[],"funding":[]},"route":"/companies/johnson-johnson/","neighbours":{"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/"}],"trial":[{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/"},{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/"}],"indication":[{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"institution":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/"}]}}